HCM Stock - HUTCHMED (China) Limited
Unlock GoAI Insights for HCM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $630.20M | $838.00M | $426.41M | $356.13M | $227.98M |
| Gross Profit | $281.32M | $453.55M | $115.31M | $97.89M | $39.46M |
| Gross Margin | 44.6% | 54.1% | 27.0% | 27.5% | 17.3% |
| Operating Income | $-43,705,000 | $18.38M | $-409,770,000 | $-344,288,392 | $-198,616,285 |
| Net Income | $37.73M | $100.78M | $-360,835,000 | $-194,648,000 | $-125,730,000 |
| Net Margin | 6.0% | 12.0% | -84.6% | -54.7% | -55.2% |
| EPS | $0.22 | $0.60 | $-2.15 | $-1.25 | $-0.90 |
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 22nd 2025 | Morgan Stanley | Downgrade | Underweight | $13.75 |
| May 13th 2025 | HSBC Securities | Downgrade | Hold | - |
| November 24th 2023 | Deutsche Bank | Upgrade | Buy | - |
| May 4th 2022 | Deutsche Bank | Downgrade | Hold | - |
Earnings History & Surprises
HCMEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 17, 2026 | — | — | — | — |
Q1 2026 | Mar 17, 2026 | — | — | — | — |
Q3 2025 | Aug 7, 2025 | $1.46 | $1.30 | -11.0% | ✗ MISS |
Q2 2025 | May 9, 2025 | — | — | — | — |
Q1 2025 | Mar 19, 2025 | $-0.09 | $0.01 | +107.6% | ✓ BEAT |
Q3 2024 | Sep 30, 2024 | — | $0.01 | — | — |
Q3 2024 | Jul 31, 2024 | — | $0.01 | — | — |
Q1 2024 | Mar 19, 2024 | — | $0.01 | — | — |
Q1 2024 | Feb 28, 2024 | $-1.08 | $-0.04 | +96.3% | ✓ BEAT |
Q3 2023 | Jul 31, 2023 | — | $0.10 | — | — |
Q2 2023 | Jun 27, 2023 | — | $0.10 | — | — |
Q1 2023 | Feb 28, 2023 | $-1.02 | $-0.12 | +88.5% | ✓ BEAT |
Q3 2022 | Aug 1, 2022 | $-1.02 | $-0.19 | +81.2% | ✓ BEAT |
Q3 2021 | Sep 30, 2021 | — | $-0.05 | — | — |
Q3 2021 | Jul 28, 2021 | $-0.37 | $-0.11 | +71.5% | ✓ BEAT |
Q3 2020 | Sep 30, 2020 | — | $-0.05 | — | — |
Q3 2020 | Jul 30, 2020 | $-0.27 | $-0.05 | +81.9% | ✓ BEAT |
Q1 2020 | Mar 31, 2020 | — | $-0.02 | — | — |
Q3 2019 | Sep 30, 2019 | — | $-0.05 | — | — |
Q1 2019 | Mar 31, 2019 | — | $-0.03 | — | — |
Latest News
Reported Earlier, HUTCHMED Begins First-In-Human Global Clinical Program For ATTC Candidate HMPL-A251 In Solid Tumors
📈 PositiveReported Sunday, HUTCHMED Expands Multi-Level China Reimbursement As NRDL Continues Key Medicines And Commercial Insurance Drug List Includes TAZVERIK
📈 PositiveReported Earlier, HUTCHMED Announces Enrollment Completion In SAFFRON Global Phase III Trial Of ORPATHYS And TAGRISSO Following Progression On TAGRISSO Monotherapy
📈 PositiveReported Sunday, HUTCHMED Unveils Innovative ATTC Platform Integrating Antibodies And Small-Molecule Inhibitors To Deliver Synergistic Anti-Tumor Activity And Improved Safety
📈 PositiveHUTCHMED Presents HMPL-A251 Preclinical Data At AACR-NCI-EORTC Showing Potent HER2-Targeted PI3K/PIKK Inhibitor With Robust Antitumor Activity And Low Toxicity
📈 PositiveHUTCHMED Highlights FRUSICA-2 Data At ESMO 2025 Showing 60.5% Response Rate And Promising Outcomes In Advanced Kidney Cancer
📈 PositiveReported Earlier, HUTCHMED To Present New And Updated Clinical Data On Fruquintinib, Savolitinib And Surufatinib At ESMO Congress 2025 In Berlin
📈 PositiveMorgan Stanley Downgrades HUTCHMED (China) to Underweight, Lowers Price Target to $13.75
📉 NegativeHUTCHMED shares are trading higher after the company announced new and updated data from several studies of compounds discovered will be presented at the 2025 World Conference on Lung Cancer.
📈 PositiveReported Earlier, HUTCHMED To Present Updated Savolitinib Data In NSCLC At World Conference On Lung Cancer 2025 Including SACHI And SAVANNAH Studies
📈 PositiveReported Sunday, HUTCHMED Appoints Johnny Cheng As Acting Chief Executive Officer Following Dr Weiguo Su's Leave Of Absence For Health Reasons
➖ NeutralReported Earlier, HUTCHMED Progresses SANOVO Phase III Lung Cancer Trial of ORPATHYS And TAGRISSO Toward NMPA Submission With Enrollment Now Complete
📈 PositiveFrequently Asked Questions about HCM
What is HCM's current stock price?
What is the analyst price target for HCM?
What sector is HUTCHMED (China) Limited in?
What is HCM's market cap?
Does HCM pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to HCM for comparison